Elanco To Reduce Approx. 380 Positions, Incl. Approx. 20% Of Senior Management

Elanco Animal Health Incorporated (ELAN) announced proposed structural changes to
simplify the organization. The restructuring will eliminate approximately 380 positions around the world, including reducing the company's senior management by approximately 20%.

Executive committee members Racquel Harris Mason, executive vice president and Chief Marketing Officer, Dirk Ehle, executive vice president and president Elanco Europe, and Joyce Lee, executive vice president and president U.S. Pet Health and Commercial Operations will exit Elanco on December 31, 2021.

The company expects to record a fourth quarter 2021 pre-tax charge for severance costs of between $86 million to $94 million in connection with the restructuring, reducing fourth quarter reported GAAP net income by $65 million to $71 million and per share results by approximately $0.13 to $0.15.

The company noted that there is no change to the previously disclosed 2021 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT